{"doc_id": "32641226", "type of study": "Therapy", "title": "", "abstract": "Sacubitril/Valsartan in Advanced Heart\u00a0Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial.\nThe PARADIGM-HF (Prospective Comparison of Angiotensin II Receptor Blocker Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart\u00a0Failure) trial reported that sacubitril/valsartan (S/V), an angiotensin receptor-neprilysin inhibitor, significantly reduced mortality and heart failure (HF) hospitalization in HF patients with a reduced ejection fraction (HFrEF).\nHowever, fewer than 1% of patients in the PARADIGM-HF study had New York Heart Association (NYHA) functional class IV symptoms.\nAccordingly, data that informed the use of S/V among patients with advanced HF were limited.\nThe LIFE (LCZ696 in Hospitalized Advanced Heart\u00a0Failure) study was a 24-week prospective, multicenter, double-blinded, double-dummy, active comparator trial that compared the safety, efficacy, and tolerability of S/V with those of valsartan in patients with advanced HFrEF.\nThe trial planned to randomize 400 patients\u00a0\u226518 years of age with advanced HF, defined as an EF\u00a0\u226435%, New York Heart Association functional class IV symptoms, elevated natriuretic peptide concentration (B-type natriuretic peptide [BNP]\u00a0\u2265250 pg/ml or N-terminal pro-B-type natriuretic peptide [NT-proBNP]\u00a0\u2265800 pg/ml), and\u00a0\u22651 objective finding of advanced HF.\nFollowing a 3- to 7-day open label run-in period with S/V (24\u00a0mg/26\u00a0mg twice daily), patients were randomized 1:1 to S/V titrated to 97\u00a0mg/103\u00a0mg twice daily versus 160\u00a0mg of V twice daily.\nThe primary endpoint was the proportional change from baseline in the area under the curve for NT-proBNP levels measured through week 24.\nSecondary and tertiary endpoints included clinical outcomes and safety and tolerability.\nBecause of the COVID-19 pandemic, enrollment in the LIFE trial was stopped prematurely to ensure patient safety and data integrity.\nThe primary analysis consists of the first 335 randomized patients whose clinical follow-up examination results were not severely impacted by COVID-19.\n(Entresto\u00a0[LCZ696] in Advanced Heart\u00a0Failure [LIFE STUDY] [HFN-LIFE]; NCT02816736).\nCopyright \u00a9 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.\n", "Evidence Map": {"Enrollment": [{"term": "Advanced Heart Failure", "negation": "affirmed", "UMLS": {}, "start": 26, "end": 48}, {"term": "Heart Failure", "negation": "affirmed", "UMLS": {}, "start": 199, "end": 212}, {"term": "Hospitalized Advanced Heart Failure", "negation": "affirmed", "UMLS": {}, "start": 21, "end": 56}, {"term": "advanced HF", "negation": "affirmed", "UMLS": {}, "start": 66, "end": 77}, {"term": "Heart", "negation": "affirmed", "UMLS": {}, "start": 114, "end": 119}, {"term": "IV symptoms", "negation": "affirmed", "UMLS": {}, "start": 149, "end": 160}, {"term": "elevated natriuretic peptide concentration", "negation": "affirmed", "UMLS": {}, "start": 163, "end": 205}, {"term": "natriuretic peptide", "negation": "affirmed", "UMLS": {}, "start": 172, "end": 191}, {"term": "BNP", "negation": "affirmed", "UMLS": {}, "start": 237, "end": 240}, {"term": "pro-B-type natriuretic peptide [ NT-proBNP ]", "negation": "affirmed", "UMLS": {}, "start": 270, "end": 314}, {"term": "Advanced Heart Failure", "negation": "affirmed", "UMLS": {}, "start": 25, "end": 47}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Sacubitril / Valsartan in Advanced Heart Failure With Reduced Ejection Fraction : Rationale and Design of the LIFE Trial .", "Evidence Elements": {"Participant": [{"term": "Advanced Heart Failure", "negation": "affirmed", "UMLS": {}, "start": 26, "end": 48}], "Intervention": [{"term": "Valsartan", "negation": "affirmed", "UMLS": {}, "start": 13, "end": 22}], "Outcome": [{"term": "Ejection Fraction", "negation": "affirmed", "UMLS": {}, "start": 62, "end": 79}], "Observation": [{"term": "Reduced", "negation": "affirmed", "UMLS": {}, "start": 54, "end": 61}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "The PARADIGM-HF ( Prospective Comparison of Angiotensin II Receptor Blocker Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure ) trial reported that sacubitril / valsartan ( S / V ) , an angiotensin receptor-neprilysin inhibitor , significantly reduced mortality and heart failure ( HF ) hospitalization in HF patients with a reduced ejection fraction ( HFrEF ) .[SEP]", "Evidence Elements": {"Participant": [{"term": "Heart Failure", "negation": "affirmed", "UMLS": {}, "start": 199, "end": 212}], "Intervention": [{"term": "Angiotensin II Receptor Blocker Neprilysin", "negation": "affirmed", "UMLS": {}, "start": 44, "end": 86}, {"term": "Angiotensin-Converting Enzyme Inhibitor", "negation": "affirmed", "UMLS": {}, "start": 102, "end": 141}, {"term": "valsartan (", "negation": "affirmed", "UMLS": {}, "start": 248, "end": 259}, {"term": "V )", "negation": "affirmed", "UMLS": {}, "start": 264, "end": 267}], "Outcome": [{"term": "Mortality", "negation": "affirmed", "UMLS": {}, "start": 172, "end": 181}, {"term": "Morbidity", "negation": "affirmed", "UMLS": {}, "start": 186, "end": 195}, {"term": "mortality", "negation": "affirmed", "UMLS": {}, "start": 339, "end": 348}, {"term": "heart failure ( HF ) hospitalization", "negation": "affirmed", "UMLS": {}, "start": 353, "end": 389}], "Observation": [{"term": "significantly reduced", "negation": "affirmed", "UMLS": {}, "start": 317, "end": 338}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "However , fewer than 1 % of patients in the PARADIGM-HF study had New York Heart Association ( NYHA ) functional class IV symptoms .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "New York Heart Association ( NYHA )", "negation": "affirmed", "UMLS": {}, "start": 66, "end": 101}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Accordingly , data that informed the use of S / V among patients with advanced HF were limited .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "V", "negation": "affirmed", "UMLS": {}, "start": 48, "end": 49}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "The LIFE ( LCZ696 in Hospitalized Advanced Heart Failure ) study was a 24-week prospective , multicenter , double-blinded , double-dummy , active comparator trial that compared the safety , efficacy , and tolerability of S / V with those of valsartan in patients with advanced HFrEF .", "Evidence Elements": {"Participant": [{"term": "Hospitalized Advanced Heart Failure", "negation": "affirmed", "UMLS": {}, "start": 21, "end": 56}], "Intervention": [{"term": "V", "negation": "affirmed", "UMLS": {}, "start": 225, "end": 226}], "Outcome": [{"term": "safety", "negation": "affirmed", "UMLS": {}, "start": 181, "end": 187}, {"term": "efficacy", "negation": "affirmed", "UMLS": {}, "start": 190, "end": 198}, {"term": "tolerability", "negation": "affirmed", "UMLS": {}, "start": 205, "end": 217}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "The trial planned to randomize 400 patients \u226518 years of age with advanced HF , defined as an EF \u226435 % , New York Heart Association functional class IV symptoms , elevated natriuretic peptide concentration ( B-type natriuretic peptide [ BNP ] \u2265250 pg / ml or N-terminal pro-B-type natriuretic peptide [ NT-proBNP ] \u2265800 pg / ml ) , and \u22651 objective finding of advanced HF .", "Evidence Elements": {"Participant": [{"term": "advanced HF", "negation": "affirmed", "UMLS": {}, "start": 66, "end": 77}, {"term": "Heart", "negation": "affirmed", "UMLS": {}, "start": 114, "end": 119}, {"term": "IV symptoms", "negation": "affirmed", "UMLS": {}, "start": 149, "end": 160}, {"term": "elevated natriuretic peptide concentration", "negation": "affirmed", "UMLS": {}, "start": 163, "end": 205}, {"term": "natriuretic peptide", "negation": "affirmed", "UMLS": {}, "start": 172, "end": 191}, {"term": "BNP", "negation": "affirmed", "UMLS": {}, "start": 237, "end": 240}, {"term": "pro-B-type natriuretic peptide [ NT-proBNP ]", "negation": "affirmed", "UMLS": {}, "start": 270, "end": 314}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Following a 3- to 7-day openlabel run-in period with S / V ( 24 mg / 26 mg twice daily ) , patients were randomized 1:1 to S / V titrated to 97 mg / 103 mg twice daily versus 160 mg of V twice daily .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "V", "negation": "affirmed", "UMLS": {}, "start": 57, "end": 58}, {"term": "V", "negation": "affirmed", "UMLS": {}, "start": 57, "end": 58}, {"term": "V", "negation": "affirmed", "UMLS": {}, "start": 57, "end": 58}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "The primary endpoint was the proportional change from baseline in the area under the curve for NT-proBNP levels measured through week 24 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "proportional change from baseline in the area under the curve for NT-proBNP levels", "negation": "affirmed", "UMLS": {}, "start": 29, "end": 111}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Secondary and tertiary endpoints included clinical outcomes and safety and tolerability .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "clinical outcomes", "negation": "affirmed", "UMLS": {}, "start": 42, "end": 59}, {"term": "safety", "negation": "affirmed", "UMLS": {}, "start": 64, "end": 70}, {"term": "tolerability", "negation": "affirmed", "UMLS": {}, "start": 75, "end": 87}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Because of the COVID-19 pandemic , enrollment in the LIFE trial was stopped prematurely to ensure patient safety and data integrity .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "The primary analysis consists of the first 335 randomized patients whose clinical follow-up examination results were not severely impacted by COVID-19 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "( Entresto [ LCZ696 ] in Advanced Heart Failure [ LIFE STUDY ] [ HFN-LIFE ] ; NCT02816736 ) .", "Evidence Elements": {"Participant": [{"term": "Advanced Heart Failure", "negation": "affirmed", "UMLS": {}, "start": 25, "end": 47}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2020 American College of Cardiology Foundation . Published by Elsevier Inc . All rights reserved .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}